Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
|
|
- Ophelia Nelson
- 6 years ago
- Views:
Transcription
1 Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease Mark Lazarev, MD Summary Inflammatory bowel disease (IBD) is a complex disease that is costly both in terms of medical costs and quality of life. The major goal of treating IBD is to induce and maintain remission. An evolving goal is to completely heal the intestinal mucosa. There are a variety of effective agents for IBD. Better use of these agents is occurring with the use of top-down therapy and the targeting of those patients most likely to have complications for aggressive therapy. Key Points IBD is a significant, costly disease that impacts quality of life. Ulcerative colitis primarily affects the colon, whereas Crohn s disease can affect the entire GI tract. Treatments include 5-amiosalicylic acid derivatives, thiopurines, TNF inhibitors, and natalizumab. Therapy is moving to a top-down approach with more aggressive therapy being used earlier. Mucosal healing is becoming a goal of treatment. Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract, which affects up to 1.4 million persons in the United States. It is typically divided into ulcerative colitis (UC) and Crohn s disease (CD). IBD generally presents in people in their teens or 20s. A few predisposing factors for developing IBD include genetics, gastrointestinal infections, nonsteroidal anti-inflammatory medication uses, and antibiotics. The prevalence of IBD is 120 to 200 per 100,000 for UC and 50 to 200 per 100,000 for CD in the Western world. 1 The U.S., Canada, and some parts of Europe and Scandinavia have very high rates. It is unclear why the rate is so high in these countries and continues to increase but it may be related to increased recognition, increased use and abuse of antibiotics, heavily processed food diets, and increased hygiene. In non-westernized countries, many people are colonized with helminthes and bacteria that may protect against autoimmune diseases. The direct medical costs for IBD are significant. IBD patients are more likely to have emergency room visits, hospitalizations and surgeries than patients without IBD. Hospital costs make up a significant portion of costs of an IBD patient. This disease also significantly impacts quality of life. UC is a diffuse mucosal inflammation limited to the colon; it almost always affects the rectum, and it may extend proximally in a symmetrical, uninterrupted pattern to involve all or part of the large intestine. 2,3 CD, by contrast, is a patchy, transmural inflammation that may involve any part of the gastrointestinal tract from mouth to anus. Based on population-based and health care claims databases, UC affects approximately 250,000 to 500,000 people in the U.S. Between 7000 and 46,000 persons are newly diagnosed with UC annually. Common symptoms include rectal bleeding, urgency, frequency, and systemic signs of toxicity in more severe disease (fever, weight loss, anemia, elevated inflammatory markers). Most people have moderate symptoms and are controlled by conventional therapies (Exhibit 1). 3,4 UC is associated with frequent outpatient medical visits, hospitalizations, and high drug and hospitalization costs due to relapses in disease activity. Thirty to 40 percent of UC 22 Journal of Managed Care Medicine Vol. 17, No. 1
2 Exhibit 1: Ulcerative Colitis 3,4 100% Fulminant Disease (9%) 80% Patients with UC 60% 40% Moderate to Higher Activity (71%) 20% 0% Low Activity (20%) Disease Activity patients ultimately require colectomy during their disease course, whether for medically refractory symptoms, fulminant colitis or dysplasia/cancer. Crohn s disease is a chronic inflammatory disorder of the entire gastrointestinal tract. The primary symptoms are chronic, occasionally bloody diarrhea and crampy abdominal pain. There are 10,000 to 47,000 new diagnoses annually. Up to 30 percent of patients can develop perianal CD with abscesses, fistulas, and fissures. Traditionally, up to 75 percent of patients will require at least one surgery. IBD is diagnosed based on symptoms, laboratory tests, bowel studies, and bowel biopsies. Exhibit 2 compares the advantages and disadvantages of the various methods for assessing structural features of IBD. In most cases, CD is readily distinguished from UC by clinical, radiologic, endoscopic, and pathologic features. Biomarkers are increasingly being used to distinguish between UC and CD. Autoantibodies and antibody levels against various bacteria can be used to measure the amount of inflammation within the body. Increasing amounts of immune reactivity has been shown to indicate increasing disease complications and more aggressive disease phenotypes in adults and children with CD. 5 Fecal calprotectin, another biomarker which is frequently used, is elevated with increased mucosal inflammation in IBD. Fecal calprotectin represents 40 to 60 percent of cytosolic proteins in neutrophils. The amount of calprotectin in feces is therefore proportional to the neutrophil migration to the gastrointestinal mucosa. It accurately distinguishes IBD from non-ibds such as irritable bowel syndrome and furthermore predicts clinical relapse in IBD patients. It has been found to be more sensitive and specific than other inflammatory markers such as erythrocyte sedimentation rate (ESR). Currently, there is no cure for CD. The only cure for ulcerative colitis is taking out the colon. Thus, all but the patients with the mildest of disease will need to be on chronic, lifelong therapy. Because these are chronic conditions, medication adherence can be an issue. Once patients are feeling well, they are less likely to continue their medications, which can lead to a disease flare-up. The goals of therapy are to induce and maintain a clinical remission, avoid complications of the disease, achieve a good quality of life, and minimize short- and long-term toxicity. The medications for IBD include 5-aminosalicylic acid (ASA) agents, corticosteroids, thiopurines, anti-tnf agents, and natalizumab. Each class has benefits and risks in treating IBD. The 5-ASA agents are considered the safest agents for IBD. They have been used for decades. They are anti-inflammatory but are not immunosuppressives. They are effective for induction and maintenance of remission of mild to moderate ulcerative colitis. These come in multiple different forms including oral tablets and rectal topicals. Oral agents include sulfasalazine [Azulfidine ] and mesalamine [Pen- Vol. 17, No. 1 Journal of Managed Care Medicine 23
3 Exhibit 2: Methods for Assessing Structural Features in IBD Ileocolonoscopy Advantages Validated, widely available Sensitive to changes Prognostic value Disadvantages Limited to luminal structures Incomplete examinations 20% Small Bowel follow through Widely available Detection penetrating/stricturing complications Patient tolerance Radiation exposure Bowel transit time No information about extraenteric disease, misses mild disease CT MRI Widely available, reproducible Less interobserver variation Fast study Extraenteric structures High sensitivity & specificity Reproducible over time Extraenteric structures No radiation Better for perianal disease Radiation exposure and overuse Misses mild disease Limited availability Heterogeneity in image acquisition and interpretation Have to lie still for appropriate breath-holding sequences Misses mild disease Wireless Capsule Endoscopy Detects more small bowel lesions than cross-sectional imaging Widely available Heterogeneity in interpretation Lower specificity for Crohn s disease Capsule retention tasa, Asacol, Lialda, Apriso ]. Rectal topicals include mesalamine enema [Rowasa ] or suppository [Canasa ]. Often, combination therapy with oral and rectal 5-ASA works better than oral alone. For proctitis, topical ASA can be used alone. The 5-ASA agents are generally very safe and well tolerated. With some formulations, there is a need to take up to 12 pills a day. A minority of patients will actually get worse on this class of medications. Interstitial nephritis can rarely be caused by 5-ASA agents and thus kidney function needs to be monitored at least once a year. Corticosteroids are effective in the induction, but not maintenance of remission in both CD and UC. The most commonly used steroids are prednisone and budesonide [Entocort ]. In UC, steroids are usually used with active flare-ups when 5-ASAs are not working. This usually involves starting prednisone at 40mg a day, and tapering over eight to 10 weeks. In CD involving the small intestines and right colon (the most common locations), budesonide is preferred over prednisone. Budesonide has fewer systemic side effects because of the way it is metabolized. The long-term risks of steroids are well known and significant. They include diabetes, hypertension, increased risk of infection, osteopenia and osteoporosis, avascular necrosis of the hip, weight gain, cataracts, skin thinning and bruising, hormonal imbalance, and anger, anxiety or other psychiatric effects. Overall, 55 percent of patients on corticosteroids will have an adverse event and will have to discontinue therapy. Historically, patients with CD on corticosteroids have a high likelihood of becoming steroid dependent or requiring surgery. Because of the risks, long-term treatment of IBD with steroids is inappropriate and should be avoided. Thiopurines (azothioprine [Imuran ], 6-mercaptopurine) are steroid-sparing oral agents. They are purine-antagonist anti-metabolites that interfere with nucleic acid synthesis in white blood cells, especially in T-lymphocytes, which are important in the production of inflammatory mediators. Thiopurines are effective in maintaining remission in CD and UC in about 50 percent of patients. They are usually started when 5-ASAs are not enough to control moderate to severe symptoms or for steroid dependence. They have no role for inducing a remission because it takes two to four months for maximum effectiveness. The thiopurines are usually combined with a steroid taper to initiate therapy. Thiopurines can cause some significant adverse 24 Journal of Managed Care Medicine Vol. 17, No. 1
4 Exhibit 3: ACG Guidelines for CD (2009) Mild to moderate disease - Sulfasalazine at 3-6g/d for colonic disease - Budesonide for ileal/right colon disease Moderate to severe disease - Prednisone for induction - Azathioprine for maintenance of remission - Anti-TNFs for patients with inadequate response with steroids, immunomodulators Infliximab and infliximab/azathioprine more effective than azathioprine alone - Natalizumab for patients with inadequate response to anti-tnf Exhibit 3: ACG Guidelines for UC (2010) 7,8 Mild to moderate disease - Sulfasalazine at (4-6g/d) 5-ASAs - Thiopurines for patients who don t respond to steroids - Infliximab for patients steroid refractory or dependent who have failed thiopurine Moderate to severe disease - 5-ASAs effective in reducing relapses - Thiopurines for maintenance of remission - Infliximab effective for induction and maintenance events, including leukopenia, increased risk for infection, elevated liver function tests, pancreatitis, allergic reaction, and fatigue. One adverse effect of major concern is the increased risk for lymphoma. The risk of non-hodgkin s lymphoma with longterm use of thiopurines is about four to five times that of the general population. 6 The chances of getting lymphoma in the general population is two out of 10,000. The risk with thiopurines is nine out of 10,000, but the absolute risk is still low. This risk has to be compared with the risk of not taking the medication and achieving remission. Patients will have to be closely monitored especially when a thiopurine is first started. Overall, about 10 percent of patients will need to stop the medication because of an adverse event. Tumor necrosis factor (TNF) levels are elevated in the serum, stool, and intestinal tissues of patients with inflammatory bowel diseases, and it may play a pivotal role in the pathogenesis of CD. The anti-tnf biologic agents are approved for induction and maintenance of remission for CD (infliximab [Remicade ], adalimumab [Humaria ], certolizumab [Cimzia ]) and UC (infliximab, adalimumab, golimumab [Simponi ]). They are usually started when 5-ASAs or thiopurines are not enough to control moderate to severe symptoms, or for steroid dependence. Anti-TNF agents are the most effective therapy available for perianal fistulizing disease. The anti-tnf agents have some well-known, adverse events including immediate or delayed infusion or injection site reaction and increased risk for infection. The risk of lymphoma related to these agents is unknown. Overall, about 10 percent of patients will have an adverse event, but only one in 250 events will be serious. Because of the risk of significant immunosuppression, caution must be taken in combining these medications with steroids for an extended period. Additionally, up to 50 percent of patients will lose response to anti-tnf agents over time. In this case, a switch to another anti-tnf agent can be made, but the second agent is usually less effective. Natalizumab [Tysabri ] is a humanized monoclonal antibody against the cell adhesion molecule α4- integrin. The drug is believed to work in IBD by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines. It is effective in inducing and maintaining remission in CD. This agent is administered as a once- monthly infusion. It is usually started in patients who have failed an anti-tnf agent and for whom surgery is not a good option. Patients must be off all immunosuppressants other than steroids before starting this agent. The potential adverse effect of most concern with Vol. 17, No. 1 Journal of Managed Care Medicine 25
5 Exhibit 4: AGA IBD QI Measures 2012 PQRS 1. Document disease activity and severity 2. Recommend steroid-sparing therapy after 60 days 3. Assess bone health if steroid-exposed 4. Recommend influenza vaccine 5. Recommend pneumococcal vaccine 6. Document recommendation for cessation of smoking 7. Assess for HBV status pre-anti-tnf 8. Assess for latent TB pre-anti-tnf Exhibit 4: CCFA Process Measures 9,10 Test for TB before anti-tnf therapy Test for C. difficile in flares Flex sig. for CMV in steroid-refractory hospitalized UC Check TPMT before starting thiopurines Recommend steroid-sparing agents if >4m steroids Recommend colectomy or close surveillance for low-grade dysplasia in colitis Recommend smoking cessation if smoker with CD Educate patients regarding vaccinations HBV = Hepatitis B virus; TB = Tuberculosis; CMV = Cytomegalovirus; TPMT = Thiopurine S-methyltransferase (ability to metabolize thiopurines) Steroid-free clinical remision Days lost from work/school Days hospitalized ED visits Malnutrition Anemia Normal health related QOL Narcotic use Nighttime BMs or leakage Incontinence Exhibit 4: CCFA Outcome Measures natalizumab is progressive multifocal leukoencephalopathy (PML). There is a one in 1000 risk of developing PML while on natalizumab. It is a concerning event because it is very often fatal or debilitating if acquired. The major risk factors for developing PML are John Cunningham (JC) virus exposure, prior immunosuppressives, and natalizumab use greater than 24 months. Patients on natalizumab need close monitoring with neurologic exams. If it does not work in the first three months, it should be discontinued. Exhibit 3 outlines the A level recommendations for CD and UC from the American College of Gastroenterology guidelines. 7,8 Additionally, the American Gastroenterological Association (AGA) and Crohn s and Colitis Foundation of America (CCFA) have published quality and process measures in IBD which can be used to assess care for these patients (Exhibit 4). 9,10 Traditionally, when a patient was diagnosed, the least toxic agents were started and then therapy would be moved forward once failure occurred. Top-down therapy refers to starting with the most aggressive therapy rather than the least. This method is most applicable to CD and refers to starting an anti-tnf agent, often with a thiopurine agent, as initial therapy. New data are emerging that combination therapy may be most effective early in the course of disease. The hope is that early aggressive treatment will decrease complication, hospitalization and surgery rates. There is a need to weigh the benefits and risks of combination therapy. It is important to try to predict at diagnosis those patients who will have an aggressive course with complications. Currently, this prediction is made based on severity of disease based on initial presentation, level of immune markers, and bowel study findings. Increasingly, the management of IBD is moving toward mucosal healing as a goal of therapy. Studies are now using mucosal healing as a marker of medication efficacy. There is evidence that patients in clinical remission who also achieve mucosal healing are less likely to flare over time. Clinical remission of symptoms does not always mean that mucosal healing has occurred. Currently our medications do an overall poor job at achieving mucosal healing. There is no clear consensus as to how we should strive to achieve mucosal healing as a goal of therapy. 26 Journal of Managed Care Medicine Vol. 17, No. 1
6 An area of frequent concern for patients is whether anti-tnf or thiopurine therapy can be stopped. In most cases, therapy cannot be safely stopped without a significant risk of relapse. In patients on an anti-tnf agent in combination with a thiopurine agent, a subset of patients may be able to stop the thiopurine. In order to stop a medication, patients should have clinical and endoscopic remission, as well as have no elevated markers of inflammation and mucosal healing. We are only now learning which factors predict the ability to come off medication. Sometimes medical therapy is inappropriate. Examples include patients with recurrent obstructive episodes from scarred down stricture that is best approached with surgery, extensive fistulizing disease or abscess within the abdomen which needs surgery (followed by medical therapy). It is important to address these situations with surgery. There is a growing push to use more biologic agents in IBD. Biologics have been shown to decrease the rate of hospitalization and surgery. A recent systematic review in Crohn s disease, found that infliximab and adalimumab were cost effective when given as induction therapy followed by episodic therapy for five years. 11 It is unclear if biologics are still cost effective when given as maintenance therapy. Episodic therapy is only using the agent when the patient is having a flare-up, but this strategy is not as effective as maintenance therapy nor is it recommended by any guidelines. A few new agents are under development for IBD. Vedolizumab, similar to natalizumab but without the risk of PML, is being studied for both UC and CD. Tofacitinib is an oral agent beginning Phase III study for UC. Ustekinumab is in Phase III trials for CD. Conclusion IBD is a complex, heterogeneous condition that affects patients for many decades. It causes significant morbidity and associated costs to society. Effective medications are available, but can be very expensive and thus need to be used wisely. Mark Lazarev, MD is an Assistant Professor of Medicine at the Johns Hopkins University School of Medicine. References 1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6): Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn s disease and ulcerative colitis in Olmsted County, Minnesota, Inflamm Bowel Dis. 2007;13(3): Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6): Langholz E, Munkholm P, Nielsen OH, et al. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to Scand J Gastroenterol. 1991;26(12): Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101(2): Siegel CA. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment Pharmacol Ther. 2011;33(1): Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn s disease in adults. Am J Gastroenterol. 2009;104(2): Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3): AGA. Adult Inflammatory Bowel Disease Physician Performance Measures Set Available at IBD_Measures.pdf 10. Melmed GY, Siegel CA, Spiegel BM, et al. Quality indicators for inflammatory bowel disease: development of process and outcome measures. Inflamm Bowel Dis. 2013;19(3): Tang DH, Harrington AR, Lee JK, et al. A systematic review of economic studies on biological agents used to treat Crohn s disease. Inflamm Bowel Dis. 2013;19(12): Vol. 17, No. 1 Journal of Managed Care Medicine 27
Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease
Mark Lazarev, MD November 14, 2013 Assistant Professor of Medicine, Johns Hopkins University School of Medicine Best Practices in the Diagnosis and Treatment of Inflammatory Bowel Disease 1 Talk outline
More informationUnderstanding Inflammatory Bowel Diseases (IBD):
Understanding Inflammatory Bowel Diseases (IBD): What Every Patient Needs to Know William H Holderman, MD Digestive Health Specialists Tacoma, WA Today s Objectives Define IBD, its potential causes and
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationI B D. etter than this. isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES
I B D m etter than this isease UNDERSTANDING INFLAMMATORY BOWEL DISEASES What types of people have learned how to manage their IBD? Athletes Musicians Firefighters DOCTORS HEROES Artists Presidents Actors
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationTreatment Options. Suresh Pola, MD Kaiser San Diego
Treatment Options Suresh Pola, MD Kaiser San Diego Overview of Treatments! Medications! Diet! Complementary and Alternative Medicines! How to treat Pain Treatment Goals and Target! Goals of Treatment should
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationTreating Crohn s and Colitis in the ASC
Treating Crohn s and Colitis in the ASC Kimberly M Persley, MD Texas Digestive Disease consultants TASC Meeting Outline IBD 101 Diagnosis Treatment Burden of Disease Role of ASC Inflammatory Bowel Disease
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationGarrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor
Garrick Brown, MD Digestive Health Specialists Tacoma Gig Harbor Today s Objectives Define IBD, its potential causes and diagnosis Discuss management and treatment Discuss complementary and alternative
More informationCertain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.
Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationCrohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine
Crohn's disease Crohn's disease is an inflammatory condition of the digestive tract that affects children and adults. Common features of Crohn's disease include mouth sores, diarrhea, abdominal pain, weight
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationMy Child Has Inflammatory Bowel Disease : Why? What now? What s next?
My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationOutline. Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic. Biologic Drugs. Biologic Drugs. Biologic Drugs Anti-TNF
Outline Biologic Drugs in Inflammatory Bowel Disease Dr. Jason Etzel MD The Vancouver Clinic Types of biologic drugs How do they work? How effective are they? Safety/Toxicity concerns with biologics Biologic
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationCarefirst.+.V Family of health care plans
Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationINFLAMMATORY BOWEL DISEASE. Brittany Palasik, PharmD, BCPS University of North Texas System College of Pharmacy
INFLAMMATORY BOWEL DISEASE Brittany Palasik, PharmD, BCPS University of North Texas System College of Pharmacy Pharmacist learning objectives By the end of this presentation, the pharmacist should be able
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCOPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease
Inflammatory Bowel Disease What Every Clinician Needs to Know Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease Beth Israel Deaconess Medical Center Associate Professor of Medicine Harvard
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationULCERATIVE COLITIS. Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC
ULCERATIVE COLITIS Sean Lynch, MD and Richard Bloomfeld, MD Wake Forest University School of Medicine Winston-Salem, NC What is Ulcerative Colitis? Ulcerative colitis (UC) is a disease marked by inflammation
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationDisease Management Strategies for Moderate to Severe IBD in Adults
Disease Management Strategies for Moderate to Severe IBD in Adults Alyssa Parian, MD Assistant Professor of Medicine Johns Hopkins University April 21, 2016 Outline Overview of IBD Treatments (Benefits/Risks)
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationIdentifying and Managing Patients with IBD at Risk for Progressive Disease
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationPractical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center
Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators
More informationIBD Module 2: Medication and Patient Management. Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics
IBD Module 2: Medication and Patient Management Kami Roake, PharmD Rheumatology & Gastroenterology Pharmacist University of Utah Hospitals & Clinics Objectives Describe current treatment guidelines and
More informationWhat is Crohn's disease?
What is Crohn's disease? Crohn's disease is a chronic inflammatory disorder that causes inflammation of the digestive tract. It can affect any area of the GI tract, from the mouth to the anus, but it most
More informationUnderstanding Your Benefits and Risks
IBD Treatment Options Understanding Your Benefits and Risks benefit risk assessment tool Understand your options. Improve your health... and life. Inflammatory bowel disease (IBD) is two, separate disorders
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Tysabri (natalizumab) MP-042-MD-WV Provider Notice Date: 10/01/2017 Original Effective Date: 11/01/2017 Annual Approval Date:
More informationThis program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda
This program is supported by an educational grant from Janssen Biotech Inc., Shire, Inc., and a sponsorship from Takeda Today s Presenter Adam S. Cheifetz, MD Director, Center for Inflammatory Bowel Disease
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationInflammatory Bowel Disease
Inflammatory Bowel Disease Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Crohn's disease andulcerative colitis are the principal types of inflammatory
More informationTop 10 Things you need to know about IBD. Suresh Pola, MD Kaiser San Diego
Top 10 Things you need to know about IBD Suresh Pola, MD Kaiser San Diego Top 10 Things to Know: IBD What you can eat How to treat the pain Not all diarrhea is a flare Ways to reduce your risk of getting
More informationInflammatory Bowel Diseases
Objectives Today s discussion will address the following topics: Similarities and differences between Crohn s disease (CD) and ulcerative colitis (UC) Risks and benefits of medication, surgery, and integrative
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationWhich is the Safest Strategy to Treat Moderate to Severe IBD?
Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor
More informationMedical therapies and IBD
Medical therapies and IBD Although there is no cure for IBD, there are many treatment options available. There is no standard treatment for IBD that is effective in all situations or for all patients,
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationDr David Epstein Vincent Pallotti Hospital and University of Cape Town
Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease
More information10/23/2014. Program Goals
Program Goals Help you understand ulcerative colitis and its effects Review current treatments, including medications, and surgery Provide tips for managing your disease through diet and complementary
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationWhat Will This Talk Cover? 101: The Basics of Inflammatory Bowel Disease. Terms & Abbreviations. What Is Normal GI Anatomy?
101: The Basics of Inflammatory Bowel Disease What Will This Talk Cover? What is IBD? What causes it? What are complications of it? How do I find out if I have IBD? How do we treat IBD? Jennifer Choi,
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More informationINFLAMMATORY BOWEL DISEASE. Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic
INFLAMMATORY BOWEL DISEASE Jean-Paul Achkar, MD Center for Inflammatory Bowel Disease Cleveland Clinic WHAT IS INFLAMMATORY BOWEL DISEASE (IBD)? Chronic inflammation of the intestinal tract Two related
More informationOPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG
1C: Advances in Inflammatory Bowel Disease OPTIMAL USE OF IMMUNOMODULATORS AND BIOLOGICS Edward V. Loftus, Jr., MD, FACG narrow interpretation of this presentation topic would A be a discussion of dosing
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationObjectives. Overview 11/4/2014. Modern Management of Inflammatory Bowel Disease Daniel J. Stein MD Assistant Professor Medical College of Wisconsin
Modern Management of Inflammatory Bowel Disease Daniel J. Stein MD Assistant Professor Medical College of Wisconsin Objectives Review of Crohn s Disease and UC Approach to Therapy Summarize the benefits
More informationThe ABCs of Inflammatory Bowel Disease. Jennifer Choi, M.D. Associate Director March 31, 2012
The ABCs of Inflammatory Bowel Disease Jennifer Choi, M.D. Associate Director March 31, 2012 What Will This Talk Cover? What is IBD? What causes it? What are complications of it? How do I find out if I
More informationAddressing Risks and Benefits In IBD
Addressing Risks and Benefits In IBD Gil Y. Melmed, MD, MS Assistant Professor of Medicine, Cedars-Sinai Medical Center David Geffen School of Medicine at UCLA www.nomorecrohnsdisease.com "Jaw Dropping
More informationP a g e 1. Inflammatory Bowel Disease Guidelines
P a g e 1 Inflammatory Bowel Disease Guidelines Introduction Inflammatory bowel disease (IBD) is a chronic inflammatory disease affecting the gastrointestinal (GI) system. It is comprised of two major
More informationBridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists
ORIGINAL ARTICLE Annals of Gastroenterology (2017) 30, 1-5 Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-ibd gastroenterologists Mohammad
More informationSpeaker Introduction
Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: CP.PHAR.265 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Entyvio) Reference Number: CP.PHAR.265 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationIBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital
IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital Aims To understand the aetiology of IBD To understand the impact that
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationNew Perspectives on the Diagnosis and Management of IBD. Disclosures
New Perspectives on the Diagnosis and Management of IBD Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children's Hospital/Atlantic Health Professor of Pediatrics Icahn School of Medicine
More informationWhat is Inflammatory Bowel Disease (IBD)?
INFLAMMATORY BOWEL DISEASE (IBD) What is Inflammatory Bowel Disease (IBD)? Inflammatory bowel disease, or IBD, is when there is inflammation, or swelling, in the gastrointestinal (GI) tract and a lifelong
More informationEffective Health Care Program
Comparative Effectiveness Review Number 131 Effective Health Care Program Pharmacologic Therapies for the Management of Crohn s Disease: Comparative Effectiveness Executive Summary Description of Crohn
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationWhat is ulcerative colitis?
What is ulcerative colitis? Ulcerative colitis is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. Ulcers form where inflammation has killed the cells
More informationINFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE
INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE Symptoms The symptoms of Crohn s disease can vary from person to person, based on where the disease is in the body and how bad the inflammation is. The
More informationThe Road to Remission
The Road to Remission Understanding, Treating and Living with Inflammatory Bowel Disease IBDCenterOrlando.com As many as 1.5 million Americans currently suffer from inflammatory bowel disease (IBD), and
More informationThis program is supported by an educational grant from Janssen Biotech Inc, and a sponsorship from Takeda.
This program is supported by an educational grant from Janssen Biotech Inc, and a sponsorship from Takeda. Objectives Today s discussion will address the following topics: Similarities and differences
More informationThe Spectrum of IBD. Inflammatory Bowel Disease. Symptoms. Epidemiology. Tests for IBD. CD or UC? Inflamatory Bowel Disease. Fernando Vega, M.D.
The Spectrum of IBD Inflammatory Bowel Disease Fernando Vega, M.D. Epidemiology CD and UC together 1:400 UC Prevalence 1:500 UC Incidence 6-12K/annum CD Prevalence 1:1000 CD Incidence 3-6K/annum Symptoms
More informationCrohn s Disease. Resident Lecture 1/17/19
Crohn s Disease Resident Lecture 1/17/19 Objectives Features/Classification of Crohn s Disease Medical Treatment Surgical Indications Surgical Considerations 2 Case 25 yo F presents to your office with
More informationOutcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience
Outcomes of immunosuppressors and biologic drugs in inflammatory bowel Treatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationImplementation of disease and safety predictors during disease management in UC
Implementation of disease and safety predictors during disease management in UC DR ARIELLA SHITRIT DIGESTIVE DISEASES INSTITUTE SHAARE ZEDEK MEDICAL CENTER JERUSALEM Case presentation A 52 year old male
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationUlcerative Colitis: State of the Art 2006
Ulcerative Colitis: State of the Art David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Improving Management of Ulcerative Colitis (UC) Better classification/diagnostic
More informationUlcerative Colitis. ulcerative colitis usually only affects the colon.
Ulcerative Colitis Introduction Ulcerative colitis is an inflammatory bowel disease. It is one of the 2 most common inflammatory bowel diseases. The other one is Crohn s disease. Ulcerative colitis and
More information